Q2 revenues grew 5.3% YoY to | 8553 crore (I-direct estimate: | 8069 crore). US formulations grew 4.3% YoY to | 2492 crore amid currency tailwinds and specialty traction. India business remained flattish (up 0.7%) YoY at | 2531 crore whereas Emerging Markets business grew 10.4% YoY to | 1559 crore. RoW markets business grew 16.3% YoY to | 1322 crore. EBITDA margins expanded 361 bps YoY to 25.6% (I-direct estimate of 22.5%) mainly due to a better product mix (higher specialty sales) and lower other expenditure. Delta vis--vis I-direct estimates was mainly due to lower staff costs and...